共 56 条
[1]
Clark R(1998)Small-cell lung cancer: treatment progress and prospects Oncology (Williston Park) 12 647-658
[2]
Ihde DC(1993)Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease database Cancer 72 1184-1191
[3]
Albain KS(2006)Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer J Clin Oncol 24 5441-5447
[4]
Crowley JJ(1999)Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 658-667
[5]
Hutchins L(2000)A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis Lung Cancer 30 23-36
[6]
O’Brien M(1998)Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients Eur J Clin Pharmacol 54 509-514
[7]
Ciuleanu T(1999)Topotecan—a novel topoisomerase I inhibitor: pharmacology and clinical experience Oncology 56 1-12
[8]
Tsekov H(1992)Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice Int J Cancer 50 760-766
[9]
Von Pawel J(1997)Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule-dependent process Cancer Res 57 1425-1428
[10]
Schiller JH(1998)Combination of irinotecan and etoposide for treatment of refractory of relapsed small-cell lung cancer J Clin Oncol 16 3329-3334